SCIENCE
Technology
ADCs with V-001 payload
Antibody + Cleavable Linker + Payload
(V-001)
Targets
"Bystander" effect -- kills neighboring tumor cells lacking target via payload diffusion
Superior Efficacy
Outperforms current standards in breast, ovarian, colon, and NSCLC.
MDR Advantage
Excels in multi-drug resistant breast cancer lines versus Camptothecin analogs (e.g., SN-38).
Enhanced Safety
Demonstrates a favorable therapeutic index in healthy cells and pediatric trials.
Targeted Delivery
Formulations (parenteral and ADCs) optimized for PIK3CA-mutated patient populations.
De-Risked ADCs
Utilizes validated antibodies and linker chemistries.
BREAST CANCER WITH PIK3CA MUTATIONS
NCI-60 DATA: V-001 OUTPERFORMS CURRENT STANDARDS OF CARE INCLUDING SN-38 (TRODELVY© PAYLOAD) IN BREAST CANCER WITH PIK3CA MUTATIONS
V-001
Doxorubicin
Paclitaxel
Vincristine
SN-38
Growth is relative to the no-drug control, and relative to the time zero number of cells. This allows detection of both growth inhibition (values between 0 and 100) and lethality (values less than 0).
NCI-60 data for Doxorubicin, Paclitaxel, Vincristine & SN-38 available from https://dtp.cancer.gov
MULTI-DRUG RESISTANT BREAST CANCER
NCI-60 DATA: V-001 outperforms camptothecin analogs (state-of-the-art ADC payloads) INCLUDING SN-38 (TRODELVY© PAYLOAD) IN MULTI-DRUG RESISTANT BREAST CANCER
NCI-60 DATA: V-001 SHOWS SUPERIOR EFFICACY TO CAMPTOTHECIN ANALOGS INCLUDING SN-38 (TRODELVY© PAYLOAD) IN MULTI-DRUG RESISTANT BREAST CANCER
V-001
Topotecan
Irinotecan
SN-38
Growth is relative to the no-drug control, and relative to the time zero number of cells. This allows detection of both growth inhibition (values between 0 and 100) and lethality (values less than 0).
NCI-60 data for Topotecan, Irinotecan & SN-38 available from https://dtp.cancer.gov
Growth is relative to the no-drug control, and relative to the time zero number of cells. This allows detection of both growth inhibition (values between 0 and 100) and lethality (values less than 0).
NCI-60 data for Topotecan, Irinotecan & SN-38 available from https://dtp.cancer.gov
TRIPLE NEGATIVE BREAST CANCER
NCI-60 DATA : V-001 Outperforms current standards of care including SN-38 (TRODELVY© PAYLOAD) IN TRIPLE NEgaTIVE BREAST CANCER
V-001
Doxorubicin
Paclitaxel
Vincristine
SN-38
Growth is relative to the no-drug control, and relative to the time zero number of cells. This allows detection of both growth inhibition (values between 0 and 100) and lethality (values less than 0).
Potential Indications for HER-2
OVARIAN CANCER HER-2
NCI-60 DATA : V-001 OUTPERFORMS CAMPTOTHECIN ANALOGS INCLUDING SN-38 (TRODELVY© PAYLOAD) IN OVARIAN CANCER HER-2 EXPRESSING CELL LINES
V-001
Topotecan
Irinotecan
SN-38
NON SMALL CELL LUNG CANCER (NSCLC) HER-2
NCI-60 DATA : V-001 OUTPERFORMS CAMPTOTHECIN ANALOGS INCLUDING SN-38 (TRODELVY© PAYLOAD) IN NON SMALL CELL LUNG CANCER (NSCLC) HER-2 EXPRESSING CELL LINES
V-001
Topotecan
Irinotecan
SN-38
Potential Indications for EGFR
COLON CANCER EGFR
NCI-60 DATA : V-001 OUTPERFORMS CAMPTOTHECIN ANALOGS INCLUDING SN-38 (TRODELVY© PAYLOAD) IN COLON CANCER EGFR EXPRESSING CELL LINES
V-001
Topotecan
Irinotecan
SN-38
NON SMALL CELL LUNG CANCER (NSCLC) EGFR
NCI-60 DATA : V-001 OUTPERFORMS CAMPTOTHECIN ANALOGS INCLUDING SN-38 (TRODELVY© PAYLOAD) IN NON SMALL CELL LUNG CANCER (NSCLC) EGFR EXPRESSING CELL LINES
V-001
Topotecan
Irinotecan
SN-38
V-001 VERSUS FDA-APPROVED EGFR INHIBITORS IN EGFR OVEREXPRESSING CELL LINES
NCI-60 DATA : V-001 OUTPERFORMS FDA-APPROVED EGFR INHIBITORS IN EGFR OVEREXPRESSING CELL LINES
V-001
Osimertanib
Erlotinib
Afatinib
Gefitinib
